Clinical trials: Primary Open Angle Glaucoma or Ocular Hypertension
- Condition Primary Open Angle Glaucoma or Ocular Hypertension
- Funder type Industry (pharma, biotech, devices)
Glaucoma, Open-angle
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
- Trial name
- NCT00801437
- Testing
- Xalacom
- Where
- 39 sites in Slovakia
- Volunteers
- 457 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT07913074
- Testing
- Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Tavo Biotherapeutics
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Primary Open Angle Glaucoma, Ocular Hypertension
Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
To compare intraocular pressure lowering effectiveness of a new fixed combination drug.
- Trial name
- NCT01062971
- Testing
- dorzolamide-timolol-brimonidine
- Where
- Mexico
- Volunteers
- 124 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open Angle Glaucoma, Ocular Hypertension
A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04863365
- Testing
- PHP-201 ophthalmic solution
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- pH Pharma
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Open-angle Glaucoma, Ocular Hypertension
Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.
- Trial name
- SEE-1 (NCT02179008)
- Testing
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- Santen Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to…
- Trial name
- NCT06964191
- Testing
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting.
- Trial name
- NCT01568008
- Testing
- Bimatoprost 0.01% ophthalmic solution
- Where
- Belgium
- Volunteers
- 933 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate whether the TUG device is safe and effective in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02858284
- Testing
- TUG
- Volunteers
- 25 people
- Sponsor
- EyeSonix
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
- Trial name
- NCT02059278
- Testing
- T-2345, Xalatan
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Nephron Pharmaceuticals Corporation
Glaucoma
A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)
The purpose of this study is to evaluate the safety and tolerability of INS117548 ophthalmic solution.
- Trial name
- NCT00767793
- Testing
- INS117548
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC